Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors

BACKGROUND: Avapritinib, a novel inhibitor of KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18‐mutant unresectable or metastatic gastrointestinal stromal tumors (U/M GISTs). We assessed the safety of avapritinib and provide evidence‐based guidance on management of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Joseph, Cissimol P., Abaricia, Sarah N., Angelis, Michelle A., Polson, Kathleen, Jones, Robin L., Kang, Yoon‐Koo, Riedel, Richard F., Schöffski, Patrick, Serrano, César, Trent, Jonathan, Tetzlaff, Eric D., Si, Tuan Dong, Zhou, Teresa, Doyle, Ashley, Bauer, Sebastian, Roche, Maria, Havnaer, Tracy
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Gastrointestinal Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018323/
https://ncbi.nlm.nih.gov/pubmed/33301227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13632
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados